SpringerLink
Log in

Evaluation the Survival of Patients with Gastric Cancer Treated with Adjuvant or Palliative Chemotherapy

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Aim

Our aim was to evaluate impact of chemotherapy (5-fluorouracil plus docetaxel and cisplatin) on the survival of gastric cancer cases.

Method

Seventy-nine patients were eligible to take part in this study between November 2006 and April 2013, who received 5-fluorouracil (700 mg/m2, 21-h infusion within 5 days), cisplatin (60 mg/m2 on day 3), and Docetaxel (60 mg/m2 on day 2). Radiotherapy was added to the treatment only in the cases with entire stomach body cancer (positive margin) and with giant ulcer (above 50 mm) in proximal gastric cancer.

Results

Twenty-four patients were female and 55 were male. The median age was 54. In this study, 54 % of the tumors were located in the proximal and 46 % in the distal of stomach. Seventy five percent of patients were at stage I–III (adjuvant chemotherapy), and 25 % at stage IV (palliative chemotherapy). Ninety-one percent of the patients at stages I–II, 68.3 % of the patients at stage III, and one out of 20 patients at stage IV were alive at the end of follow-up. Median disease-free survival for the patients at stages I–III was 63 months, and the overall survival for all patients was 50 months.

Conclusion

The results of our study indicate that the survival of the patients with stomach cancer increases with chemotherapy. Radiotherapy was used for our patients with gastric cancer in specific cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. American Cancer Society. Cancer facts and figs. 2012. Atlanta, Ga: American Cancer Society; 2012.

    Google Scholar 

  2. Mousavil SM, Somi MH. Gastric cancer in Iran 1966-2006. Asian Pac J Cancer Prev. 2009;10:407–12.

    Google Scholar 

  3. Atherton JC. The pathogenesis of helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol. 2006;1:63–96.

    Article  CAS  PubMed  Google Scholar 

  4. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer. 2007;10(2):75–83 .Epub 2007 Jun 25

    Article  PubMed  Google Scholar 

  6. Fu**o Y, Mizoue T, Tokui N, Kikuchi S, Hoshiyama Y, Toyoshima H, et al. Cigarette smoking and mortality due to stomach cancer: findings from the JACC study. J Epidemiol. 2005;15(Suppl 2):S113–9.

    Article  PubMed  Google Scholar 

  7. Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265(10):1287–9.

    Article  CAS  PubMed  Google Scholar 

  8. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German gastric cancer study. Ann Surg. 1998;228:449–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer. 1992;70(5):1030–7.

    Article  CAS  PubMed  Google Scholar 

  10. Harrison LE, Karpeh MS, Brennan MF. Proximal gastric cancers resected via a transabdominal-only approach. Ann Surg. 1997;225(n°6):678–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Okabayashi T, Kobayashi M, Nishimori I, Sugimoto T, Namikawa T, Onishi S, et al. Clinicopathological features and medical management of early gastric cancer. Am J Surg. 2008;195:229–32.

    Article  PubMed  Google Scholar 

  12. Ryu KW, Choi IJ, Doh YW, Kook MC, Kim CG, Park HJ, et al. Surgical indication for non-curative endoscopic resection in early gastric cancer. Ann Surg Oncol. 2007;14(12):3428–34.

    Article  PubMed  Google Scholar 

  13. Natsugoe S, Arigami T, Uenosono Y, Yanagita S, Nakajo A, Matsumoto M, et al. Lymph node micrometastasis in gastrointestinal tract cancer—a clinical aspect. Int J Clin Oncol. 2013;18(5):752–61. doi:10.1007/s10147-013-0577-y .Epub 2013 Jun 18

    Article  PubMed  Google Scholar 

  14. Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Ohro S, et al. Recurrence in early gastric cancer--presence of micrometastasis in lymph node of node negative early gastric cancer patient with recurrence. Hepato-Gastroenterology. 2007;54(74):620–4.

    PubMed  Google Scholar 

  15. Sonoda H, Tani T. Clinical significance of molecular diagnosis for gastric cancer lymph node micrometastasis. World J Gastroenterol. 2014;20(38):13728–33 . doi:10.3748/wjg.v20.i38.13728.Published online 2014 Oct 14

    Article  PubMed  PubMed Central  Google Scholar 

  16. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  17. Villanueva MT. Combination therapy: update on gastric cancer in East Asia. Nature Reviews Clinical Oncology. 2011;8:690. doi:10.1038/nrclinonc.2011.171.

    Article  PubMed  Google Scholar 

  18. Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol. 2007;14(10):2687–90 .Epub 2007 Jul 27

    Article  PubMed  Google Scholar 

  19. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33. doi:10.1200/JCO.2011.36.7136 .Epub 2012 May 14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Foo M, Leong T. Adjuvant therapy for gastric cancer: current and future directions. World J Gastroenterol. 2014;20(38):13718–27.

    Article  PubMed  PubMed Central  Google Scholar 

  21. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37. doi:10.1001/jama.2010.534.

    Article  Google Scholar 

  22. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J, et al. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg. 2004;91:283–7.

    Article  CAS  PubMed  Google Scholar 

  23. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.

    Article  PubMed  Google Scholar 

  24. Lustosa SA, Saconato H, Atallah AN, Lopes Filho Gde J, Matos D. Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials. Acta Cir Bras. 2008;23:520–30.

    Article  PubMed  Google Scholar 

  25. Tanizawa Y, Terashima M. Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric Cancer. 2010;13:137–48.

    Article  PubMed  Google Scholar 

  26. Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 2010;65(6):1009–21. doi:10.1007/s00280-010-1256-6 .Epub 2010 Feb 4

    Article  CAS  PubMed  Google Scholar 

  27. World GI (2016) Press Release: Chemoradiotherapy after surgery for gastric cancer shows similar outcomes to post-operative chemotherapy. 30 Jun 2016

  28. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163–8.

    Article  CAS  PubMed  Google Scholar 

  29. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. V-325 study group. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group. J Clin Oncol. 2007;25(22):3205–9.

    Article  CAS  PubMed  Google Scholar 

  30. Ajani JA, Fodor M, Van Cutsem E, Tjulandin S, Moiseyenko V, Cabral F, et al. Multinational randomized phase II trial of docetaxel and cisplatin with or without 5-fluorouracil in patients with advanced gastric cancer or GE junction adenocarcinoma. Proc Am Soc Oncol. 2000;19:247.

    Google Scholar 

  31. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003;14(Suppl 2):ii41–4.

    PubMed  Google Scholar 

  32. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line chemotherapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991–7.

    Article  CAS  PubMed  Google Scholar 

  33. Shah MA. Update on metastatic gastric and esophageal cancers. JCO. 2015;33(no. 16):1760–9.

    Article  CAS  Google Scholar 

  34. Mousavi1,2,3* SM, Somi2 MH. Gastric cancer in Iran 1966-2006. Asian Pacific J Cancer Prev. 10:1–4.

  35. Roth AD, Maibach R, Fazio N, Pagani O, Morant R, Stupp R, et al. 5-FU as protracted continuous i.v. infusion can be added to full dose taxotere–cisplatin in advanced gastric carcinoma (AGC). Eur J Cancer. 1999;35(Suppl 4):S139.

    Article  Google Scholar 

  36. Nadler SH, Moore GE. A clinical study of fluorouracil. Surg Gynecol Obstet. 1968;127:1210–4.

    CAS  PubMed  Google Scholar 

  37. James M. Metz Margaret K. Hampshire OncoLink Patient Guide: Colorectal Cancer page 103 edithion2

  38. Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M, Artho G, Thirlwell MP. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2012;23(6):1512–7.

    Article  CAS  PubMed  Google Scholar 

  39. Veisani Y, Delpisheh A. Survival rate of gastric cancer in Iran; a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2016;9:78–86.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Talaghani & Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Mozaffar Aznab

  2. Kermanshah University of Medical Sciences, Kermanshah, Iran

    Omid Beiki

  3. Karolinska Institutet, Tomtebodavägen 18A, Floor 5, 171 77, Stockholm, Sweden

    Omid Beiki

  4. Imam Reza Hospital, Kermanshah University of Medical Sciences, Shahid Beheshti BLND, Kermanshah, 6714415333, Iran

    Kiumars Eslam pia, Khosro Setayeshi, Mohamad Ali Hesami & Houshang Vrae

Authors
  1. Mozaffar Aznab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omid Beiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kiumars Eslam pia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Khosro Setayeshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohamad Ali Hesami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Houshang Vrae
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mozaffar Aznab.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

There is no funding source.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aznab, M., Beiki, O., pia, K.E. et al. Evaluation the Survival of Patients with Gastric Cancer Treated with Adjuvant or Palliative Chemotherapy. J Gastrointest Canc 48, 31–37 (2017). https://doi.org/10.1007/s12029-016-9868-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-016-9868-7

Keywords

Search

Navigation